Revance Therapeutics (RVNC) Competitor Comparison
We are evaluating the key criteria listed to compare Revance Therapeutics (RVNC) against its competitors in the Biotechnology industry.
Market Capitalization
169 / 368Gross Profits
173 / 278Total Revenue
57 / 300EBITDA
290 / 337Free Cashflow
308 / 352Quick Ratio
221 / 357Earnings per Share
218 / 359Dividend yield
0 / 6Total Cash
113 / 358Performance 3 years
214 / 368Performance 5 years
221 / 368Performance 10 years
214 / 368Linearity 3 years
87 / 368Linearity 5 years
79 / 368Linearity 10 years
69 / 368Total Rank
249 / 368Dividend Rank
261 / 368Valuation Rank
299 / 368Piotroski Rank
237 / 368Muliplier Rank
38 / 368Valuation Rank - RVNC ranking 299 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.